Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
US12083136B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 31, 2019 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Jan 2, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.